Senior Manager Biostatistics
Avalo Therapeutics
Senior Manager Biostatistics
Avalo Therapeutics
Develops IL-1beta-targeting biologics for inflammation
At Avalo (ahh-vah'-low), we are 100% focused on developing treatments for immune-mediated inflammatory diseases with large unmet needs that affect millions worldwide. Our strategy is to develop medicines that target the IL-1β pathway, which is a central driver of the inflammatory process.
We share a commitment to teamwork, passion for science, and dedication to patients suffering from acute and chronic inflammatory disorders. Our collective expertise in discovery, development, and regulatory approvals is evidenced in our strong individual track records of advancing multiple therapeutic programs to successful commercialization.
Position Summary:
Senior Manager / Associate Director, Biostatistics to provide strategic and operational statistical leadership across clinical development programs. This individual will serve as the lead biostatistician for one or more clinical development programs and will partner closely with Clinical Development, Medical Affairs, Data Management, Statistical Programming, Regulatory Affairs, and external partners to ensure the delivery of high-quality statistical strategy, analyses, and regulatory submissions.
The successful candidate will contribute to study design, protocol development, analysis planning, interpretation of clinical data, regulatory interactions, and evidence generation activities that support development, registration, and lifecycle management of Avalo's programs. This role offers the opportunity to influence development strategy, advance innovative statistical methodologies, and contribute to regulatory and business decision-making across the organization.
Essential Duties and Responsibilities:
Statistical Leadership & Clinical Development
Study Design, Analysis & Reporting
Regulatory & External Interactions
Medical Affairs, HEOR & Evidence Generation
Vendor Oversight & Operational Excellence
Required Education and Experience:
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1–4% of the population globally. Avalo is pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb. For more information about Avalo, please visit www.avalotx.com.
ATTENTION: External Agencies and Placement Firms
A member of the Avalo Human Resources Department will contact an agency directly if an open position is eligible to be sourced from an outside recruiting service. Avalo does not accept unsolicited resumes from employment agencies for any employment opportunity. All agencies/recruiters must have a written agreement/SOW in place with Avalo and prior to submitting any resume or CV.
All resumes must be submitted through the appropriate process. Any resumes submitted without an agreement and/or any resumes sent unsolicited through e-mail accounts of Avalo employees will be considered outside of the appropriate process, do not imply or create any obligation on our part, do not impart any restrictions on Avalo with respect to the hiring of any persons whose resumes are so submitted and are not eligible for placement fees.
Develops IL-1beta-targeting biologics for inflammation
Avalo Therapeutics develops biologic therapies that target the IL-1beta pathway for immune-mediated inflammatory diseases. Its lead candidate, abdakibart (AVTX-009), is a humanized monoclonal antibody that inhibits IL-1beta and blocks downstream inflammatory signaling, advancing toward a registrational Phase 3 program after positive Phase 2 results in hidradenitis suppurativa. AVTX-010 is a long-acting next-generation anti-IL-1beta antibody designed to extend dosing intervals. The company focuses on research and development of novel biologics with commercialization expected through pharmaceutical partnerships and product sales. Unlike some competitors that pursue broader or different inflammatory targets, Avalo concentrates specifically on IL-1beta–related inflammation with a pipeline aimed at improving dosing convenience and clinical outcomes in inflammatory diseases.
Explore more opportunities at Avalo Therapeutics